TYK Medicines' (HKG:2410) new drug application for Asandeutertinib was accepted by China's National Medical Products Administration, according to a Friday Hong Kong bourse filing.
The acceptance is for the indication of first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.